Professor, Pediatrics, University of Tennessee Health Science Center College of Medicine
Pediatric Hematology & Oncology
Dr. Victor M. Santana, MD
|
|
Give Review
Victor Santana is an expert in the field of Pediatric Hematology & Oncology. He researched medicine at University of Puerto Rico School of Medicine. Victor M. Santana, MD has written publications. He has 52 publications published with PubMed. The lastest publication is: 'Safety and diagnostic accuracy of tumor biopsies in children with cancer.'
Publications
- Safety and diagnostic accuracy of tumor biopsies in children with Cancer.
- Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
- Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid Tumors.
- Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors.
- Adaptive functioning of childhood brain tumor survivors following conformal radiation therapy.
- Subsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma.
- Computerized assessment of cognitive late effects among adolescent brain tumor survivors.
- The Utility of Parent Report in the Assessment of Working Memory among Childhood Brain Tumor Survivors.
- Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid Tumors.
- Working Memory Performance among Childhood Brain Tumor Survivors.
- The role of neoadjuvant chemotherapy in children with malignant solid Tumors.
- Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study.
- A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
- Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors.
- Frontline treatment of localized osteoSarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 Trial.
- Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid Tumors.
- Zygomycosis originating from an odontogenic infection in a pediatric oncology patient.
- Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.
- Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric Sarcoma patients.
- Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid Tumors.
- Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91.
- Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid Tumors.
- Differential diagnosis and work-up of elevations of alkaline phosphatase following therapy for pediatric Cancer.
- Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood.
- Disease control intervals in high-risk neuroblastoma.
- Transfer of complex frontline antiCancer therapy to a developing country: the St. Jude osteosarcoma experience in Chile.
- Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue Sarcoma.
- Avoiding misdiagnosing neuroblastoma as Wilms tumor.
- Good clinical practice and the conduct of clinical studies in pediatric oncology.
- Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
- Significance of pleural effusion in neuroblastoma.
- Population pharmacokinetic analysis of topotecan in pediatric Cancer patients.
- Analysis of prognostic factors in ewing Sarcoma family of tumors: review of St. Jude Children's Research Hospital studies.
- Pediatric Cancers in the new millennium: dramatic progress, new challenges.
- Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
- Distinguishing benign from malignant pulmonary nodules with helical chest CT in children with malignant solid Tumors.
- Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk Sarcomas: the St. Jude Children's Research Hospital e...
- Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid Tumors.
- The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hosp...
- Percutaneous biopsy of pediatric solid Tumors.
- Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
- Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy.
- Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteoSarcoma.
- Aggressive bladder carcinoma in a child.
- Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neurob...
- Tumor rupture and mitotic index in pediatric sex cord-stromal Tumors.
- Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid Tumors.
- Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid Tumors.
- A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid Tumors.
- Clinical trials using irinotecan.
- Survival after recurrence of Ewing Tumors: the St Jude Children's Research Hospital experience, 1979-1999.
Schools
University of Puerto Rico Medical Sciences Campus
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Kaposi's Sarcoma
- View All
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
- Aetna
- Blue Card PPO
- Network S
- Great West Healthcare-Cigna PPO
- LocalPlus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- Qualchoice PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Johns Hopkins University -
University of Puerto Rico School of Medicine
Hospital
-
University of Tennessee Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. David R. Goshorn, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mari H. Dallas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory T. Armstrong, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Jane S. Hankins, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Winfred C. Wang, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Fariba Navid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raul C. Ribeiro, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Amar J. Gajjar, MB
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Hiroto Inaba, MB
This Doctor is OpenDoctor Recommended.
|